ESTRO 2025 - Abstract Book

S1477

Clinical – Mixed sites & palliation

ESTRO 2025

Figure_1: LVEF before/after STAR

Figure_2: VT burden before/after STAR

Conclusion: RAVENTA is the world's first multicenter multiplatform study of STAR for patients with refractory VT. Possibly treatment-related side effects were mild, demonstrating short-term safety of the procedure, and most patients had significant reductions in VT burden. Long-term follow-up and further optimization of the target definition is warranted.

Keywords: SBRT, STAR, Ventricular Tachycardia